On July 30, 2026, the clinical trial registry updated the status of a retatrutide study to completed. The trial, titled "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight," is registered under identifier NCT05929079. It is a Phase 3 study evaluating retatrutide, also known as LY3437943, in people who have type 2 diabetes mellitus along with obesity or overweight.
The registry entry lists the trial status as completed but does not include posted results in this update. No efficacy or safety outcomes are stated in the available data. The update reflects only a change in trial status, not a report of findings.
Retatrutide is currently listed with an approved regulatory status. This update pertains specifically to the Phase 3 trial NCT05929079 and its completion status as of the date noted. Further details on the trial, including any future results, can be found through the official registry listing.
Readers interested in background on this compound can consult the retatrutide overview for additional context.